SynerTechcare Australia Pty led by A/Prof Cheng Yuen Yee, University Technology Sydney has successfully extract an active ingredient from rice which is normally not available by ingesting rice directly. We tested this Ingredient In Vitro and In Vivo and find it can help damaged digestive organ cells to recover.
Our product got patent application grant from HK Productivity Council since 2023.
SynerTechcare Australia Pty decided to license Bionis Pharmaceutical Limted to manufacture and develop the active ingredient Bionis into a Chemotherapy Adjuvant.
We will go through all necessary tests on Bionis in our own laboratory, collaborating with universities , and with independent third laboratories. Our target is finally listed the Bionis with TGA. One of the hardest standard for Pharmaceutical products. We plan to have these done with in 4 years.
For raw material, our affiliated will collect it for us. For manufacturing we have GMP approved Manufacture in Australia. We are looking for partners inning Kong Science park to pack and bottle the products for us.
For marketing, we will leverage on our affiliated and collaborate with Pharmaceutical brands.
Our mission:
We will develop Bionis as a Chemotherapy Adjuvant to extend life expectancy of oncology patients.
A/ Prof Cheng Yuen Yee has started research on Bionis since 2016. Bionis has been given to mice which receive chemotherapy treatment, they demonstrate extended life and better quality of life.
We developed a proprietary technology which turn rice straw into Biodegradable substitute for packaging material which confirmed to be able to be reduce fruit post harvest loss. Our project will reduce plastic waste, Fruit loss and paddy burning.